- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05821959
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
A Phase 1/2 Trial of AAVAnc80-hOTOF Gene Therapy in Individuals With Sensorineural Hearing Loss Due to Biallelic Otoferlin Gene Mutations
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The following two dose levels will be tested sequentially:
- 4.1E11 total vg/cochlea
- 8.1E11 total vg/cochlea
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Akouos Clinical Trials
- Phone Number: +1 (857) 410-1816
- Email: clinicaltrials@akouos.com
Study Locations
-
-
-
Taipei City, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Wan-Cian Liao
- Phone Number: +886- 953-728-657
- Email: mulong0328@gmail.com
-
-
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Recruiting
- University of Iowa
-
Contact:
- Kesten Anderson
- Phone Number: 319-356-8320
- Email: Kesten-Anderson@uiowa.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19146
- Recruiting
- Children's Hospital of Philadelphia
-
Contact:
- Aminat Adegbuji
- Phone Number: 267-426-8380
- Email: adegbujia@chop.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 2 to 17 years old (inclusive) at the time of AAVAnc80-hOTOF administration
- Biallelic mutations in the otoferlin gene
- Clinical presentation of Profound bilateral sensorineural hearing loss as assessed by ABR
- Preserved distortion product otoacoustic emissions (DPOAEs)
- Able and willing to comply with all study requirements, including willingness to participate in a separate long term follow-up study after completion of this trial
Exclusion Criteria:
- Persistent ear infections, anatomic or other abnormalities of the ear, and/or medical conditions that would contraindicate undergoing surgery, anesthesia, and/or administration of investigational gene therapy
- Bilateral cochlear implants
- Prior participation in a clinical trial with an investigational drug, within six months prior to administration, or any prior participation in a gene therapy clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1a and Cohort 1b
Cohort 1a: Participants aged 7 to 17 years old (inclusive) to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device Cohort 1b: Participants aged 2 to 17 years old (inclusive) at the time of AAVAnc80-hOTOF administration to receive intracochlear administration of AAVAnc80-hOTOF (dose level 1) in the study ear using a sterile, one-time use investigational medical device |
AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
|
Experimental: Cohort 2
Cohort 2: Participants aged 2 to 17 years old (inclusive) at the time of AAVAnc80-hOTOF administration to receive intracochlear administration of AAVAnc80-hOTOF (dose level 2) in the study ear using a sterile, one-time use investigational medical device
|
AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of Adverse Events (AEs)
Time Frame: through trial completion, approximately 2 years
|
AEs with relationship to the investigational medicinal product and/or to the administration procedure (including the delivery device)
|
through trial completion, approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Auditory Brainstem Response (ABR) Threshold
Time Frame: through trial completion, approximately 2 years
|
Changes from baseline in ABR intensity threshold (decibels normal hearing level [dB nHL])
|
through trial completion, approximately 2 years
|
Performance of the Akouos Delivery Device
Time Frame: through trial completion, approximately 2 years
|
Performance based on the frequency of device deficiencies observed during delivery of AAVAnc80-hOTOF to the intracochlear space
|
through trial completion, approximately 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Kathy Reape, MD, Akouos, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AK-OTOF-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sensorineural Hearing Loss, Bilateral
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
MED-EL Elektromedizinische Geräte GesmbHRecruitingSensorineural Hearing Loss, Bilateral | Bilateral Hearing LossFrance
-
MED-EL Elektromedizinische Geräte GesmbHCompletedSensorineural Hearing Loss, BilateralFrance
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
-
MED-EL Elektromedizinische Geräte GesmbHRecruitingSensorineural Hearing Loss, BilateralFrance
-
MED-EL Elektromedizinische Geräte GesmbHRecruitingSensorineural Hearing Loss, BilateralFrance
-
Children's Hospital Medical Center, CincinnatiCompletedHearing Impairment | Sensorineural Hearing Loss, BilateralUnited States
-
MED-EL Elektromedizinische Geräte GesmbHCompletedSensorineural Hearing Loss, BilateralFrance
-
CochlearCompleted
Clinical Trials on AAVAnc80-hOTOF via Akouos Delivery Device
-
Windtree TherapeuticsCompletedRespiratory Distress SyndromeUnited States, Canada, Colombia, Hungary, Chile, Ireland, Netherlands, Poland